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Reply to the letter to the Editor of Nevez and Le Gal entitled  1 
“Caspofungin and Pneumocystis pneumonia: it is time to go ahead” 2 
 3 
172 words 4 
 5 
We thank Nevez and Le Gal for their interest in our work, and to underscore its importance 6 
(1). Our results strongly suggest that Pneumocystis jirovecii infecting humans is sensitive to 7 
caspofungin, like are the Pneumocystis species infecting rodents used as models. Thus, we 8 
fully agree with Nevez and Le Gal that the usefulness of caspofungin to treat Pneumocystis 9 
pneumonia should be considered for clinical use. In addition, the sensitivity of P. jirovecii to 10 
the other echinocandins used clinically will have to be characterized. Indeed, Saccharomyces 11 
cerevisiae harbors three differentially regulated genes encoding the target of the 12 
echinocandins, the catalytic subunit of the 1,3-β-glucan synthase. Despite close homology, 13 
these enzymes present drastically distinct sensitivities to the different echinocandins, 14 
caspofungin, anidulafungin, and micafungin (1-3). The Pneumocystis species infecting 15 
rodents proved to be sensitive to the three echinocandins (4, 5). Nevertheless, because the 16 
homology between the enzymes of the different Pneumocystis species is similar to that 17 
between the three S. cerevisiae enzymes (1), one cannot exclude that P. jirovecii is insensitive 18 
to anidulafungin and micafungin.  19 
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